Omega-3 fatty acids in major depressive disorder: A preliminary double-blind, placebo-controlled trial

Kuan Pin Su, Shih Yi Huang, Chih Chiang Chiu, Winston W. Shen

Research output: Contribution to journalArticlepeer-review

408 Citations (Scopus)

Abstract

Patients with depression have been extensively reported to be associated with the abnormality of omega-3 polyunsaturated fatty acids (PUFAs), including significantly low eicosapentaenoic acid and docosahexaenoic acid in cell tissue contents (red blood cell membrane, plasma, etc.) and dietary intake. However, more evidence is needed to support its relation. In this study, we conducted an 8-week, double-blind, placebo-controlled trial, comparing omega-3 PUFAs (9.6 g/day) with placebo, on the top of the usual treatment, in 28 patients with major depressive disorder. Patients in the omega-3 PUFA group had a significantly decreased score on the 21-item Hamilton Rating Scale for Depression than those in the placebo group (P

Original languageEnglish
Pages (from-to)267-271
Number of pages5
JournalEuropean Neuropsychopharmacology
Volume13
Issue number4
DOIs
Publication statusPublished - Aug 2003

Keywords

  • Diet
  • Fish intake
  • Major depressive disorder
  • Nutrition therapy
  • Omega-3 polyunsaturated fatty acids
  • Taiwan

ASJC Scopus subject areas

  • Clinical Neurology
  • Psychiatry and Mental health
  • Biological Psychiatry
  • Neurology
  • Pharmacology
  • Psychology(all)

Fingerprint Dive into the research topics of 'Omega-3 fatty acids in major depressive disorder: A preliminary double-blind, placebo-controlled trial'. Together they form a unique fingerprint.

Cite this